Peptide News Digest

#Copper Peptide

7 stories

Copper peptide is shorthand for GHK-Cu — the tripeptide-copper complex glycyl-L-histidyl-L-lysine bound to copper(II) — and the broader category of copper-containing peptides used in skincare and longevity products. Topical GHK-Cu has the strongest evidence base among research peptides, going back decades on wound healing, collagen and elastin synthesis, and anti-inflammatory effects.

2026 has been the year copper peptides crossed into mainstream consumer skincare. BoomRx launched a copper-peptide skincare line at the A4M Longevity SpringFest in April; Neurogan Health expanded with a 2% GHK-Cu topical body care backed by a 12-week clinical trial reporting 32.8% wrinkle-depth reduction and 20–30% improvement in skin firmness. Search interest in GHK-Cu has grown over 1,000% year-over-year per published trend data.

The regulatory split: topical GHK-Cu is a cosmetic ingredient, while injectable GHK-Cu sits in the FDA Category 2 reclassification queue alongside BPC-157 and others ahead of the July 23–24 PCAC meeting. Stories here cover product launches, clinical evidence, and the topical-vs-injectable distinction. See #ghk-cu, #anti-aging, and #skincare.

Industry · View digest

Sacred Eye Beauty 30-Day Ritual Launches Sunday June 28 with Inside-Out Activator (NAD+, Spermidine, Vitamin C, MODS Max Sublingual Delivery) Paired with Skin Magic Tablets Containing GHK-Cu Copper Peptide, PQQ, and Methylene Blue; Mainstream Consumer Cosmetic Peptide Wave Extends to Inside-Out Longevity Claims

Fast Millennial Mode LLC, founded by entrepreneur Elena Catalina Radu, announced the official launch of Sacred Eye Beauty's flagship 30-Day Ritual on Sunday June 28, 2026. The system has two components. The Inside-Out Activator combines NAD+, spermidine, vitamin C, and MODS Max sublingual-delivery technology in a single daily dose targeting cellular-wellness and healthy-aging markers. The Skin Magic Tablets combine GHK-Cu (copper tripeptide-1), PQQ (pyrroloquinoline quinone), and methylene blue for skin and broader cellular support. The launch fits squarely inside the 2026 mainstream-consumer cosmetic peptide wave that this site has tracked across June: Moes Group's June 6 GHK-Cu private-label manufacturing rollout, CKYN's June 20 GHK-Cu launch, Cosmetics Business's June 2026 feature on eight peptide-anchored beauty launches (Shiseido Ultimune, YSE Beauty Xtreme Glow), and the K-beauty PDRN-peptide-exosome stack. Sacred Eye's differentiator is the inside-out positioning, pairing oral supplementation with topical-equivalent claims. The consumer-channel growth runs in parallel to the regulatory thread: GHK-Cu is one of the seven peptides on the FDA Pharmacy Compounding Advisory Committee's July 23-24 agenda for 503A bulks list eligibility.

Industry · View digest

CKYN LLC Launches The Complete CKYN Protocol June 20: Three-Step GHK-Cu Copper Tripeptide Skincare System for Prestige Consumer Market — Documented 22% Firmness, 16% Fine-Line Reduction at 12 Weeks

CKYN LLC, a Kirkland, Washington-based skincare company, launched The Complete CKYN Protocol on June 20, 2026 — a three-step daily skincare system built entirely around GHK-Cu (Copper Tripeptide-1). The protocol comprises the Morning GHK-Cu Perfecting Lotion, Daytime GHK-Cu Tallow Balm, and Night-Time GHK-Cu Firming Serum. The product positioning anchors on six bioactives instead of the typical 20+ ingredient prestige skincare formulation, with concentrations targeted to clinical-study levels: published GHK-Cu research has shown 22% visibly firmer skin and 16% reduction in fine-line appearance after 12 weeks of consistent twice-daily application. GHK-Cu was first isolated from human plasma in 1973 by Dr. Loren Pickart and has accumulated four decades of cosmetic-science evidence. CKYN sits alongside Italgel avvera (June 12 launch) and GELITA CURADERM (Vitafoods Europe 2026) in the active 2026 cosmetic-peptide launch cycle.

Industry · View digest

Moes Group Opens GHK-Cu Private-Label Skincare and Haircare Manufacturing in California

Moes Group, a California-based private and white-label skincare manufacturer, announced June 6 that it is producing blue copper peptide (GHK-Cu / copper tripeptide-1) skincare and haircare formulations for brand partners, with cosmetic-grade GHK-Cu in stock and production already running. The launch arrives as the topical GHK-Cu market broadens after FDA materials in May indicated that non-injectable GHK-Cu would return to Category 1 under the 503A process; the injectable form remains pending the second PCAC review scheduled before February 2027.

Industry · View digest

Copper Peptide (GHK-Cu) Cosmetic Wave Builds Through Late May 2026 — Neurogan 2% Body Care, Auro Wellness Serum, Fastest-Growing Peptide Search Term

The copper-peptide (GHK-Cu, copper tripeptide-1) cosmetic category continued its 2026 surge through late May. Neurogan Health's 2% GHK-Cu body-care line documented a 32.8% reduction in wrinkle depth and 20-30% improvement in skin firmness in 12-week clinical testing. Auro Wellness, founded by peptide-delivery specialist Nayan Patel, anchors its copper-tripeptide serum on a proprietary delivery system. GHK-Cu is the fastest-growing peptide search term of 2026, with consumer interest spanning skin rejuvenation, hair loss, and systemic longevity. GHK-Cu activates over 4,000 human genes involved in collagen synthesis, anti-inflammation, and tissue remodeling. The cosmetic surge runs in parallel with the FDA's regulatory cycle: injectable GHK-Cu is on the docket for the February 2027 PCAC meeting alongside Melanotan II, LL-37, Dihexa, and PEG-MGF, while the topical cosmetic form remains in the lighter-regulated personal-care channel. The category illustrates the consumer end of the peptide landscape maturing alongside the therapeutic pipeline.

Industry · View digest

Neurogan Health Launches 2% GHK-Cu Copper Peptide Body Care After 12-Week Clinical Trial Showing 32.8% Wrinkle Depth Reduction and 20–30% Skin Firmness Improvement

Neurogan Health expanded its product line with a topical 2% GHK-Cu copper peptide body care, supported by a 12-week clinical trial reporting 32.8% reduction in wrinkle depth and 20–30% improvement in skin firmness. The launch lands in a 2026 GHK-Cu market characterized by surging consumer interest — the peptide is the fastest-growing skincare ingredient by search volume, with patient interest spanning skin rejuvenation, hair loss, and systemic longevity. Topical GHK-Cu has the strongest evidence base among research peptides, going back decades on wound healing and collagen synthesis, and topical applications avoid the regulatory gray zone around the injectable formulation.